Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer
Frontiers in Oncology · 29.04.2025 · 15
DOI: 10.3389/fonc.2025.1538446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 29.04.2025. Verfasst von Sara Corvigno und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Clonal hematopoiesis (CH) is characterized by the presence of hematopoietic stem cells (HSCs) with the potential of clonally expanding and giving rise to hematological malignancies. Clonal hematopoiesis of indeterminate potential (CHIP) is the outgrowth of a single HSC clone with an acquired somatic mutation in the absence of hematological abnormalities. CHIP variants occur with a variant allele frequency (VAF) of at least 2% in peripheral blood. This definition does not account for less frequent mutations that give rise to hematopoietic clones. Previous studies indicate an association between CH and secondary hematologic malignancies in cancer patients who receive chemotherapy.
Methods
To discover novel candidate CHIP mutations, including those with extremely low VAFs, we performed an in-depth characterization of low-frequency CHIP variants in a highly selected group of patients with high-grade serous ovarian cancer (HGSC) before and after neoadjuvant chemotherapy (NACT). We performed comprehensive ultra-high-depth whole-exome sequencing of circulating free DNA (cfDNA) and matched white blood cell (WBC) DNA from pre- (n=9) and post-NACT (n=9) samples from HGSC patients who had excellent response (ER; n=4) or poor response (PR; n=5) to NACT.
Results
Variants present in both the WBC DNA and cfDNA from a patient were considered candidate CHIP variants. We identified 93,088 candidate CHIP variants in 13,780 genes. Compared with pre-NACT samples, post-NACT samples tended to have fewer CHIP mutations with VAFs of less than 5%, which may reflect the negative selective pressure of chemotherapy on rare hematopoietic clones. Finally, we identified CHIP variants in tumor samples matched to the liquid biopsies.
Discussion
Our innovative sequencing approach enabled the discovery of a large number of novel low-frequency candidate CHIP mutations, whose frequency and composition are affected by chemotherapy, in the cfDNA of patients with HGSC. The CHIP variants that were enriched after chemotherapy, if validated, might become essential predictive markers for therapy-related myeloid neoplasia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Institute for Personalized Cancer Therapy (IPCT) Genomic Laboratory (IPCT Lab), Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, T…
Zitieren
APA
Corvigno, S., Yao, J., Asare, A., Zhao, L., Celestino, J., Hajek, R. A., Goette, E. A. A., Rogers, R. T., Montoya, R. N., Song, P., Zhang, Q. C., Song, X., Mohammad, M. M., Shaw, K. R., Zhang, J., Lu, K. H., Jazaeri, A. A., Westin, S. N., Sood, A. K., & Lee, S. (2025). Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1538446
Vancouver
Corvigno S, Yao J, Asare A, Zhao L, Celestino J, Hajek RA, et al. Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1538446
BibTeX
@article{Corvigno2025,
author = {Corvigno, Sara and Yao, Jun and Asare, Amma and Zhao, Li and Celestino, Joseph and Hajek, Richard A and Goette, Ency A Arboleda and Rogers, Ridge T and Montoya, Raymond N and Song, Ping and Zhang, Qingxiu C and Song, Xingzhi and Mohammad, Mohammad M and Shaw, Kenna R and Zhang, Jianhua and Lu, Karen H and Jazaeri, Amir A and Westin, Shannon N and Sood, Anil K and Lee, Sanghoon},
title = {Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1538446}
}
EUVIMED